Professor Sir Andrew Pollard, director of the Oxford Vaccine Group, has said that the UK is "going to have to live with" COVID-19, BBC News reported on Wednesday.
Prof Pollard, speaking to the Commons Science and Technology Committee, was quoted as saying that "variants and their emergence" will "continue to happen".
He added: "But in the end, we're going to have to come back to focusing on the really important public health issue, which is the hospitalisation and the death. If transmission is disconnected by vaccine immunity from the severe disease, to a large extent, then we'll need to monitor new variants, perhaps, if we need to find new vaccines and so on - but we are going to have to live with it being in our communities and transmitting."
FDA grants priority review for GSK's gepotidacin gonorrhoea indication
GSK to receive USD370m and future royalties in CureVac/BioNTech settlement
FDA lifts pause on Valneva's chikungunya vaccine IXCHIQ for elderly, updates prescribing information
Anixa Biosciences begins US FDA approved IND transfer to support Phase 2 breast cancer vaccine trial
Pfizer and BioNTech receive EU regulatory backing for LP.8.1-adapted COVID-19 vaccine
Sanofi to acquire Vicebio for USD1.15bn to strengthen respiratory vaccine pipeline
Bavarian Nordic chikungunya vaccine enters Health Canada review process
SK bioscience submits IND for Phase 1/2 clinical trial of new influenza vaccine candidate
GC Biopharma secures Vietnamese approval for varicella vaccine BARYCELA
GSK announces submission of RSV vaccine Arexvy for FDA review
PharmaJet signs MOU with Egyptian UPA and EVA Pharma to introduce needle-free vaccine delivery
Centivax raises USD45m to commercialise universal flu vaccine
CyanVac's nasal COVID vaccine shows promise in phase 1 trial
hVIVO supports Cidara Therapeutics' positive Phase 2b influenza study results